Related Experiment Video
Updated: Apr 29, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic
Hideyuki Nomura1, Yuugou Miyagi1, Hironori Tanimoto1
1The Center for Liver Disease, Shin-kokura Hospital, Kitakyushu, Japan.
Aim:
This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients.
Patients And Methods:
This study enrolled 132 older patients (age, ≥65 years) with chronic hepatitis C who received 24-48 weeks of interferon-beta plus ribavirin (FR; n = 66) or pegylated interferon-alpha plus ribavirin (PR; n = 66) therapy.
Results:
Patients with the ITPA genotype (CA/AA) in the PR group had significantly greater decreases in hemoglobin levels than those in the FR group at or after week 8. The proportions of patients with a dose reduction of interferon-beta and ribavirin in the FR group were significantly lower than those in the PR group. A significantly higher proportion of patients completed treatment in the FR group than in the PR group. The sustained virological response (intention-to-treat analysis) rate of naïve patients with genotype 1 was 29% (6 of 21) in the PR group and 29% (6 of 21) in the FR group. The sustained virological response (intention-to-treat) rate of those with genotype 2 was 67% (12 of 18) in the PR group and 72% (13 of 18) in the FR group.
Conclusion:
Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation. In treatment-naïve patients, the sustained virological response rate was similar between interferon-beta plus ribavirin therapy and pegylated interferon-alpha plus ribavirin therapy, regardless of whether the patients had hepatitis C virus genotype 1 or 2.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Hepatitis
Retroviruses
Cytomegalovirus Disease
Drug Dosing: Geriatric Patients

